辉瑞(PFE.US)旧药组合销售增长 Q1营收利润双双超预期

智通财经05-05

智通财经APP获悉，辉瑞(PFE.US)公布的第一季度利润超出华尔街预期，主要得益于对过往药物(如血液稀释剂Eliquis和抗癌药Padcev)的持续需求。根据LSEG汇编的数据，辉瑞第一季度总销售额为144.5亿美元，同比增长5.7%，高于分析师平均预期的137.9亿美元。经调整后，该公司每股收益为0.75美元，高于分析师预期的0.72美元。第一季度运营增长主要得益于老药销量的增长，包括抗癌药 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2633945459?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-05 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633945459","market":"fut","top_or_hot":-1,"title":"辉瑞(PFE.US)旧药组合销售增长 Q1营收利润双双超预期","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)公布的第一季度利润超出华尔街预期，主要得益于对过往药物(如血液稀释剂Eliquis和抗癌药Padcev)的持续需求。根据LSEG汇编的数据，辉瑞第一季度总销售额为144.5亿美元，同比增长5.7%，高于分析师平均预期的137.9亿美元。经调整后，该公司每股收益为0.75美元，高于分析师预期的0.72美元。第一季度运营增长主要得益于老药销量的增长，包括抗癌药 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1438218.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)旧药组合销售增长 Q1营收利润双双超预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)旧药组合销售增长 Q1营收利润双双超预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-05 21:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1438218.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)公布的第一季度利润超出华尔街预期，主要得益于对过往药物(如血液稀释剂Eliquis和抗癌药Padcev)的持续需求。根据LSEG汇编的数据，辉瑞第一季度总销售额为144.5亿美元，同比增长5.7%，高于分析师平均预期的137.9亿美元。经调整后，该公司每股收益为0.75美元，高于分析师预期的0.72美元。第一季度运营增长主要得益于老药销量的增长，包括抗癌药 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1438218.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1883839398.USD","symbol_name":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1438218.html","article_id":"2633945459","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633945459","pubTimestamp":1777986138,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，辉瑞公布的第一季度利润超出华尔街预期，主要得益于对过往药物的持续需求。一季度，辉瑞与百时美施贵宝联合销售的血液稀释剂Eliquis的销售额为 21.7 亿美元，同比增长 13%，而此前的估计为 17.6 亿美元。其重磅心脏药物 Vyndamax 第一季度销售额为 16 亿美元，高于此前预估的 16.2 亿美元。最近，辉瑞新冠产品的销售额已从疫情高峰期大幅下滑。辉瑞正致力于精简成本，同时重建产品线以支持未来的增长。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4534":"瑞士信贷持仓","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4585":"ETF&股票定投概念","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","PFE":"辉瑞","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4592":"伊斯兰概念","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4007":"制药","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4581":"高盛持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4599":"减肥药","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC"},"translate_title":"Pfizer (PFE.US) Old Drug Portfolio Sales Grow Q1 Revenue and Profit Both Beat Estimates","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98},"content_text":"智通财经APP获悉，辉瑞(PFE.US)公布的第一季度利润超出华尔街预期，主要得益于对过往药物(如血液稀释剂Eliquis和抗癌药Padcev)的持续需求。根据LSEG汇编的数据，辉瑞第一季度总销售额为144.5亿美元，同比增长5.7%，高于分析师平均预期的137.9亿美元。经调整后，该公司每股收益为0.75美元，高于分析师预期的0.72美元。第一季度运营增长主要得益于老药销量的增长，包括抗癌药 Padcev、血液稀释剂 Eliquis、肿瘤生物类似药和偏头痛治疗药物 Nurtec，但新冠产品收入的下降部分抵消了这一增长。一季度，辉瑞与百时美施贵宝(BMY.US)联合销售的血液稀释剂Eliquis的销售额为 21.7 亿美元，同比增长 13%，而此前的估计为 17.6 亿美元。其重磅心脏药物 Vyndamax 第一季度销售额为 16 亿美元，高于此前预估的 16.2 亿美元。新冠疫苗Comirnaty的销售额为2.32亿美元，同比下降59%，低于预期的4.34亿美元。Prevnar 系列产品创造了 16.9 亿美元的收入，同比增长 2%，高于 16.2 亿美元的预期。辉瑞表示，最近欧洲法院对其新冠疫苗的有利裁决以及其心脏药物 Vyndamax 的专利延期将有助于确保 2028 年后的更强劲增长。最新的业绩应该会让投资者松一口气，他们一直在寻找新的增长动力，以弥补因美国政府的抵制和专利即将到期而导致的新冠产品销售额下降。最近，辉瑞新冠产品的销售额已从疫情高峰期大幅下滑。辉瑞正致力于精简成本，同时重建产品线以支持未来的增长。然而，一些关键产品面临越来越大的压力，例如Prevnar和Vyndaqel等药物遭遇了新的竞争，而对新冠肺炎相关产品的需求持续下降。辉瑞公司正努力应对其一些畅销药物的专利到期问题，并一直在寻求收购以加强其药物研发管线，尤其是在减肥药物领域。该公司斥资100 亿美元收购了临床阶段肥胖症药物制造商 Metsera，并开展了多项许可和研究合作，以确保长期增长。该公司预计还将受益于上个月的法院裁决，该裁决要求波兰和罗马尼亚接受辉瑞及其合作伙伴 BioNTech(BNTX.US)生产的价值 19 亿欧元(22.2 亿美元)的新冠疫苗。辉瑞重申了其2026年的利润和营收预期，预计营收为595亿美元至625亿美元，与分析师平均预期的613.7亿美元一致。调整后摊薄每股收益预计在2.80美元至3.00美元之间(市场普遍预期2.96美元)。辉瑞董事长兼首席执行官Albert Bourla表示：“2026年开局强劲，这增强了我们对成功度过辉瑞这一关键时期的信心。我们的研发管线在多个方面取得进展——积极的3期临床试验结果和令人鼓舞的中期试验结果正在形成显著的势头——我尤其对我们在肿瘤学和肥胖症领域取得的进展感到鼓舞，我相信辉瑞在这两个领域都处于领先地位。”针对这份业绩报告， Haggerston BioHealth投资集团负责人Edmund Ingham表示：“辉瑞轻松超越了分析师对第一季度盈利的预期，调整后每股收益也表现亮眼。但正如这家陷入困境的制药公司一贯的作风，仍存在一些需要考虑的因素。净利润和调整后利润同比下降，2026年的业绩指引维持不变，并未上调;2026年没有股票回购计划;此外，关键产品(例如Eliquis和Vyndaqel)的专利悬崖也迫在眉睫。过去五年，辉瑞股价仍下跌约35%，今天的业绩不太可能推动股价全面反弹。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633945459","isCrawlerRequest":true}